Chemotherapy News and Research

Latest Chemotherapy News and Research

Researchers identify first gene mutation associated with chronic, often fatal form of neuroblastoma

Researchers have identified the first gene mutation associated with a chronic and often fatal form of neuroblastoma that typically strikes adolescents and young adults. The finding provides the first clue about the genetic basis of the long-recognized but poorly understood link between treatment outcome and age at diagnosis.

14 Mar 2012

Life-extending pill for advanced melanoma now available in UK

A life-extending pill for advanced melanoma that The Institute of Cancer Research (ICR) and The Royal Marsden Hospital helped develop is now available in the UK.

14 Mar 2012

MRI perfusion imaging can help determine brain tumor progression

Gliomas, the most common malignant brain tumors in adults, can be difficult to treat because of their aggressive and invasive nature. In treating patients with gliomas, it is increasingly important that doctors be able to detect tumor changes early when there's a better chance for recovery.

14 Mar 2012

Another role for protein Mer in novel, targeted cancer treatments

Since the mid-1990s, doctors have had the protein Mer in their sights - it coats the outside of cancer cells, transmitting signals inside the cells that aid their uncontrolled growth.

14 Mar 2012

Antidepressant could help the workings of anticancer drug used in leukemia

The study by scientists at the Institute of Cancer Research found that tranylcypromine (TCP) – which can be used to treat psychotic depressive states - can make cancer cells vulnerable to the effects of a vitamin A-derivative drug called ATRA.

13 Mar 2012

Scotland says no to prostate cancer drug Abiraterone

Patients with advanced prostate cancer in Scotland will not get access to a new drug which can extend their lives by more than three months. Prostate cancer is the most common cancer to affect men and the second most common cause of death.

13 Mar 2012

HemaQuest closes $13 million extension of Series B financing

HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that it has closed a $13 million extension of their Series B financing.

12 Mar 2012

Cancer Research UK disappointed over SMC ruling against advanced prostate cancer drug

Cancer Research UK is extremely disappointed that the advanced prostate cancer drug, abiraterone, has been ruled too expensive for routine use by the Scottish Medicines Consortium (SMC).

12 Mar 2012

Salk scientists' discovery explains how a class of chemotherapy drugs works

The well-being of living cells requires specialized squads of proteins that maintain order. Degraders chew up worn-out proteins, recyclers wrap up damaged organelles, and-most importantly-DNA repair crews restitch anything that resembles a broken chromosome. If repair is impossible, the crew foreman calls in executioners to annihilate a cell. As unsavory as this last bunch sounds, failure to summon them is one aspect of what makes a cancer cell a cancer cell.

12 Mar 2012

Researchers determine structure of concentrative nucleoside transporter

A team of researchers at Duke University has determined the structure of a key molecule that can carry chemotherapy and anti-viral drugs into cells, which could help to create more effective drugs with fewer effects to healthy tissue.

12 Mar 2012

Cancer rates to fall among men but slightly rise among women by 2020: Report

The report says that due to the growing and ageing population the actual number of new cases will rise by almost 40 per cent on 2007 levels. But when that's converted to the number of cases per 100,000 people the results are surprising. Cancer rates in men will fall from 595 to 568 cases per 100,000 by 2020. That equates to about 85,000 cases. When it comes to women the rate is projected to rise from 394 to 408 cases per 100,000. That's equivalent to 65,000 new cases in 2020.

11 Mar 2012

Maxygen reports net loss of $2.2 million for fourth quarter 2011

Maxygen, Inc., a biopharmaceutical company, today announced financial and business results for the quarter and year ended December 31, 2011.

9 Mar 2012

New hybrid aspirin shrinks tumors, curbs cancer cell growth

The humble aspirin may soon have a new role. Scientists from The City College of New York have developed a new aspirin compound that has great promise to be, not only an extremely potent cancer-fighter, but even safer than the classic medicine cabinet staple.

9 Mar 2012

Some bone marrow cells could prevent rejection of transplanted kidney in recipients: Study

Researchers transplanted certain cells from the kidney donor’s bone marrow along with the new organ. Five of eight transplant recipients who tried the method so far were off immune-suppressing medication up to 2½ years later, the researchers reported Wednesday. The preliminary results were considered important enough to be published in the journal Science Translational Medicine even though the study still is under way, because the technique worked for patients who didn’t have well-matched or related donors.

8 Mar 2012

Appendix cancer different from colon cancer

Researchers at Wake Forest Baptist Medical Center have demonstrated that cancer of the appendix is different than colon cancer, a distinction that could lead to more effective treatments for both diseases.

8 Mar 2012

Sosei initiates SO-1105 Phase I trial in oropharyngeal candidiasis

Sosei Group Corporation, the biopharmaceutical company, today announces that its wholly owned Japanese subsidiary, Sosei Co., Ltd., has initiated a Japanese Phase I trial for SO-1105 for the treatment of oropharyngeal candidiasis.

8 Mar 2012

Women with breast cancer can benefit from web-based programme

Every day 18 Swedish women are diagnosed with breast cancer. Although there is a real need for support and information, many women struggle and get lost in the deluge of information. In a study of 227 women, researchers at the Sahlgrenska Academy at the University of Gothenburg, Sweden, have developed a web-based programme to guide patients all the way from diagnosis to rehabilitation.

6 Mar 2012

Researchers identify mechanism with which cancer cells protect themselves against damage

Although many cancer drugs have already been in use for decades, their mode of action is still unknown. The new research results now challenge a mechanism of action that was previously proposed for a group of drugs and supported with experiments: the Topoisomerase I-inhibitor Camptothecin (Top1 inhibitor for short) and its derivatives used in chemotherapy, Topotecan and Irinotecan.

5 Mar 2012

Exelixis initiates cabozantinib and abiraterone phase 1 combination trial in CRPC

Exelixis Inc. today announced the initiation of a phase 1 dose-finding trial of cabozantinib in combination with abiraterone in men with metastatic castration-resistant prostate cancer (CRPC) who have disease progression following treatment with up to two prior chemotherapy regimens.

5 Mar 2012

Scientists determine chemical features of DHPS enzyme's active site

More than 70 years after the first sulfa drugs helped to revolutionize medical care and save millions of lives, St. Jude Children's Research Hospital scientists have determined at an atomic level the mechanism these medications use to kill bacteria. The discovery provides the basis for a new generation of antibiotics that would likely be harder for bacteria to resist and cause fewer side effects.

2 Mar 2012